Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|
Net Income | $0.0 | ($96.7M) | ($56.7M) | ($200.6M) | $17.4M | $12.2B | $9,942.0M | $1,006.0M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, BioNTech SE's last 12-month Net Income is ($506.6M), based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, BioNTech SE's Net Income growth was N/A. The average annual Net Income growth rates for BioNTech SE have been N/A over the past three years, 29.7% over the past five years.